Convatec Announces $1 Billion Investment to Expand R&D in the US and UK
- 3 oct
- 2 Min. de lectura
Convatec, a global leader in medical products and technologies, has announced plans to invest more than $1 billion over the next decade to accelerate its worldwide research and development (R&D) ambitions. This global, multi-year planned investment is considered a significant milestone in the company's mission to deliver breakthrough healthcare solutions and underlines Convatec’s long-standing commitment to both the United States and the United Kingdom as cornerstones of its global growth strategy.
As part of this plan, Convatec will allocate $600 million to R&D in the US over the next ten years, reaffirming its commitment to its most significant market globally. These plans include a significant expansion of its R&D facilities in Boston, United States, by the end of 2025. This expansion will increase capacity by 50% and further enhance lab, testing, and collaboration space.
In the United Kingdom, the planned investment amounts to £500 million (approximately $650 million). This figure will finance a new state-of-the-art R&D hub in Manchester, scheduled to open in 2027. This new facility is expected to be one of the largest within Convatec’s global network of Technology & Innovation Centres. This center will have the potential to provide common or shared R&D capabilities across all four of Convatec’s categories: Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. Furthermore, it will house regulatory functions, cutting-edge analytical R&D capabilities, and digital health innovation.
The decision to enhance the R&D footprint in the US and UK followed a comprehensive review of Convatec's global growth ambitions. The company already invests more than $100 million annually in R&D, representing approximately 5% of its revenue, which has delivered its strongest ever pipeline of new products.
The new Manchester R&D hub will be home to around 200 highly skilled colleagues, who will be largely transferring from Convatec’s existing R&D site in Deeside. It should be noted that Convatec’s manufacturing site in Deeside, North Wales, will remain unaffected by this change and will continue to be a cornerstone of its global operations, with around 400 employees continuing to be based there after the move completes in 2027.
Jonny Mason, Interim Chief Executive Officer of Convatec, remarked that the investment demonstrates the company's "unwavering commitment to advancing healthcare innovation for people living with chronic conditions around the world". Dr. Divakar Ramakrishnan, Chief Technology Officer and Head of Research & Development, emphasized that the expansion is an investment in the talent, technology, and infrastructure needed to accelerate innovation, reinforcing their belief in the strength of the US and UK life sciences sectors.
Once fully operational (Boston by the end of 2025 and Manchester by 2027), these flagship sites will be at the heart of Convatec’s global innovation network. The company will also sustain investment in other key European locations, such as Denmark and Slovakia, as well as its R&D teams in Mexico and the Dominican Republic.
🔖 Sources
